Phase II trial of lurbinectedin in progressive mesothelioma finalizes its patient recruitment

- **This is a single-arm, multicenter, phase II trial for the treatment of progressive malignant pleural mesothelioma.**
- **The primary endpoint of this study is progression-free survival (PFS) at 12 weeks and the results are expected early in 2019.**

Madrid, 17th of December, 2018 – The Swiss Group for Clinical Cancer Research (SAKK) has announced that the patient recruitment of the phase II trial of lurbinectedin as a single-agent for the treatment of patients with progressive malignant pleural mesothelioma has been completed.

This trial is being carried out by SAKK in collaboration with PharmaMar (MSE:PHM). It is a single-arm, multicenter Phase II trial involving 42 patients for the treatment of progressive malignant pleural mesothelioma. The primary endpoint of the study is progression-free survival (PFS) at 12 weeks and these results are expected early in 2019.

According to **Dr. Yannis Metaxas**, coordinating investigator of this trial: *"Patient recruitment has been very rapid, far faster than we expected. From what we have been able to observe so far, we hope to get first results in the first few months of 2019."*

Malignant pleural mesothelioma is a rare tumor that arises from the mesothelial cells of the pleural, peritoneal, or pericardial lining, and is often associated with asbestos exposure, usually with a very poor prognosis at the time of diagnosis. There is no cure for most malignant mesotheliomas, the goal of current cancer treatments (surgery, radiation therapy, and chemotherapy) is to reduce or eliminate symptoms as well as prolong progression-free survival (PFS) and/or overall survival (OS). There is currently no standard treatment for progressive disease.

Legal warning

This press release does not constitute an offer to sell or the solicitation of an offer to buy securities, and shall not constitute an offer, solicitation or sale in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of that jurisdiction.

About PharmaMar

Headquartered in Madrid, PharmaMar is a biopharmaceutical company, focused on oncology and committed to research and development which takes its inspiration from the sea to discover molecules with antitumor activity. It is a company that seeks innovative products to provide healthcare professionals

with new tools to treat cancer. Its commitment to patients and to research has made it one of the world leaders in the discovery of antitumor drugs of marine origin.

PharmaMar has a pipeline of drug candidates and a robust R&D oncology program. It develops and commercializes Yondelis® in Europe and has other clinical-stage programs under development for several ty-pes of solid cancers: lurbinectedin (PM1183), PM184 and PM14. With subsidiaries in Germany, Italy, France, Switzerland, Belgium, Austria and the United States. PharmaMar wholly owns other companies: GENOMICA, a molecular diagnostics company; Sylentis, dedicated to researching therapeutic applications of gene silencing (RNAi); and a chemical enterprise, Zelnova Zeltia. To learn more about PharmaMar, please visit us at www.pharmamar.com.

About lurbinectedin

Lurbinectedin (PM1183) is a compound under clinical investigation. It is an inhibitor of RNA polymerase II. This enzyme is essential for the transcription process that is over-activated in tumors with transcription addiction.

Media Contact:

Alfonso Ortín – Communications Director aortin@pharmamar.com Mobile: +34 609493127
Miguel Martínez-Cava – Digital Communication Manager mmartinez-cava@pharmamar.com Mobile: +34 606597464
Phone: +34 918466000

Investor Relations:

Phone: +34 914444500

Or please visit our website at www.pharmamar.com